Diligence memo · auto-generated · as of July 2, 2026

Cambridge Endoscopic Devices Inc

Cambridge Endoscopic Devices Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cambridge Endoscopic Devices Inc operates in Biotechnology, based in FRAMINGHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cambridge Endoscopic Devices Inc has raised $12M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.9M on 2010-04-30.

Most recent recorded round closed around 2012-07-26.

Valuation (modeled)modeled

Provath models Cambridge Endoscopic Devices Inc at approximately $130M (range $2.1M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.50× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era. Within the normal band (150% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 13.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 59% of Biotechnology peers (4293 compared).

Modeled value ranks above 63% of those peers.

Closest niche peers: Denali Medical II, Inc., Signum Biosciences, Inc., Health Elements, LLC, Nkt Therapeutics Inc, Surface Logix Inc.

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.